New Therapies for Neurological Disorders

NeurAegis is working on multiple therapeutic programs that have the potential to transform the lives of patients with neurological disorders.

Our selective calpain-2 inhibitors are being developed to address several neurological disorders related to neurodegeneration and synaptic dysfunction including concussion, epilepsy, acute glaucoma, stroke and diseases involving cognitive impairment.